Cirmtuzumab + Paclitaxel for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast Cancer
Cirmtuzumab + Paclitaxel - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study cirmtuzumab in combination with paclitaxel to see if the combination is safe and has fewer side effects than paclitaxel alone. The study will also look at how well the combination works in treating patients with HER2 negative, metastatic breast cancer.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Breast Cancer

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 2 years

12 months
Measurement of ROR1 expression levels and cancer stem cell populations
Safety and tolerability of the combination therapy since the start of any study treatment.
2 years
Time to progression
9 months
Assessment of mechanism of action through pharmacokinetic studies
Best tumor response rate
Correlates of PET/CT and cross-sectional imaging
Objective tumor response rate
Week 4
The rate of dose-limiting toxicities during the first 4 weeks of treatment

Trial Safety

Safety Progress

1 of 3

Other trials for Breast Cancer

Trial Design

1 Treatment Group

Cirmtuzumab + Paclitaxel
1 of 1
Experimental Treatment

22 Total Participants · 1 Treatment Group

Primary Treatment: Cirmtuzumab + Paclitaxel · No Placebo Group · Phase 1

Cirmtuzumab + Paclitaxel
Drug
Experimental Group · 1 Intervention: Cirmtuzumab + Paclitaxel · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Oncternal Therapeutics, IncIndustry Sponsor
5 Previous Clinical Trials
661 Total Patients Enrolled
Barbara Parker, MDLead Sponsor

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: October 7th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.